Given that lymphatic spread is a key feature of advanced CTCL, we showed that inhibition of OX-40 could potentially limit tumor dissemination through the lymphatic system, providing a novel therapeutic avenue. Here, TNFRSF4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.